Skip to main content
. 2014;16(4):172–180.

Table 1.

Gene Expression Assays

Company Assay Name Indication Result
Genomic Health Inc. (Redwood City, CA) Oncotype DX® Prostate Cancer assay Positive prostate biopsy Genomic prostate score from 0 to 100 Likelihood of freedom from higher Gleason scorea and/or non-organ-confined disease
GenomeDX Biosciences (San Diego, CA) Decipher® Post radical prostatectomy Risk of metastasis at 5 years post prostatectomy and 3 years post PSA recurrence
Myriad Genetics (Salt Lake city, UT) Prolaris® Positive prostate biopsy or Post radical prostatectomy 10-year PCSM risk or 10-year BCR risk

BCR, biochemical recurrence; PCSM, prostate cancer-specific mortality; PSA, prostate-specific antigen.

aHigh Gleason score defined as Gleason dominant pattern 4 or any Gleason pattern 5.